Targeting the Novel Long Noncoding RNA PRKCQ-AS1 for Cancer Therapy
Abstract
Cancer is the most common cause of death from disease in children. Neuroblastoma is a solid tumor in early childhood. Despite multimodality therapy, the majority of high-risk neuroblastoma patients die of the disease, and survivals suffer from long-term disabilities due to adverse side-effects from chemo- and radiotherapy at the early age. There is an urgent need to better understand its tumorigenesis and to identify novel therapies. The Focus Areas: (1) Therapy, and (2) Biology and Etiology In this project, we aim to define the novel non-protein-coding RNA, PRKCQ-AS1, as a critical driver of neuroblastoma, to identify small molecule compound inhibitors of PRKCQ-AS1 and to demonstrate their anticancer efficacy. Successful completion of this project will provide a novel targeted therapy for potential clinical translation in patients with the rare but deadly neuroblastoma.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Jan 04, 2024
- Source ID
- HT94252310714
Entities
People
- Tao Liu
Organizations
- United States Army
- University of New South Wales